SAN DIEGO, CA – May 5, 2022 – AnaBios Corporation is proud to announce that its team of experimental biologists, in partnership with a team of computational scientists from the Georgia Institute of Technology, is among the three finalists for the National Center for Advancing Translational Sciences (NCATS) 2020 ASPIRE Reduction-to-Practice Challenge. The multidisciplinary team, whose project focused on the development of a comprehensive integrated platform for translational innovation in opioid abuse, will receive a $200,000 award for reaching this important milestone in the NCATS competition.

Led by principal investigator Jeffrey Skolnick, Ph.D., from Georgia Tech, and co-investigator Andre Ghetti, Ph.D., Chief Executive Officer of AnaBios, the team has been conducting an in silico screen aimed at the identification of novel lead molecules to treat chronic pain without the risk of addiction. Virtual screening hits are being validated with AnaBios’ in vitro human primary neuron preparations, which will establish the potential of the compounds and the predictive ability of the combined approach.

The team also includes Nicole Jung, Ph.D., from the Karlsruhe Institute of Technology in Germany, and Hongyi Zhou, Ph.D., from the Georgia Institute of Technology.

The National Institutes of Health (NIH) launched the HEAL Initiative in April 2018 to improve prevention and treatment strategies for opioid misuse and addiction and enhance pain management (https://heal.nih.gov/). The NIH HEAL Initiative aims to improve treatments for chronic pain, curb the rates of opioid use disorder and overdose and achieve long-term recovery from opioid addiction.

Click here to learn more about the other winners of the 2020 NCATS ASPIRE Reduction-to-Practice Challenge (Stage 2, Milestone 2).

About AnaBios

Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies. AnaBios primarily focuses on areas of high, unmet medical need, including cardiac disease, lung disease, CNS disorders, pain and itch. As a preclinical CRO, AnaBios has the most extensive network of hospitals and transplant centers for obtaining human tissue samples from ethically consented donors for ex vivo analysis.  For more information about AnaBios, visit http://www.anabios.com.